Results 131 to 140 of about 16,087 (221)

Superior Cardiorenal Protection With Tirzepatide Over Dulaglutide in Heart Failure With Preserved Ejection Fraction: A Large‐Scale Propensity Score–Matched Real‐World Analysis

Clinical Cardiology, Volume 49, Issue 8, August 2026.
In this large real‐world propensity‐matched analysis, tirzepatide demonstrated superior reductions in mortality, hospitalizations, and cardiorenal outcomes versus dulaglutide in HFpEF patients, with a favorable safety profile. ABSTRACT Background No direct head‐to‐head trials compare tirzepatide and dulaglutide in heart failure with preserved ejection ...
Ibrahim Khalil, Md. Imran Hossain, Mst. Mahmuda Akter, Ferdous Wahid, Aizaz Anwar Khalid, Sunjida Amin Promi, Md. Abu Sayed, Mohd Turzo Rahman, Pallab Sarker   +8 more
wiley   +1 more source

Cardiovascular protection by SGLT2 inhibitors: an integrative review of mechanistic networks, clinical evidence, and safety considerations. [PDF]

Front Cardiovasc Med
Wang Z, Wang Y, Shangguan W, Li T.
europepmc   +1 more source

Myocardial Lipid Metabolism Imbalance: The Pathological Core and Novel Diagnostic‐Therapeutic Directions of Cardiovascular Diseases

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 8, August 2026.
In cardiac cells, Plin5/AMPK regulate lipid homeostasis; excess CD36‐mediated uptake drives lipotoxicity, mitochondrial dysfunction, and CVDs (e.g., heart failure). Biomarkers (ApoB/ApoA‐1) and therapies (SGLT2 inhibitors) target this cascade. ABSTRACT Cardiac lipid metabolism is fundamental to myocardial energy homeostasis, with fatty acid oxidation ...
Peiyun Xie, Qun Zeng, Hongrui Wang, Meihua She   +3 more
wiley   +1 more source

Pluronic F-127/Propylene Glycol Binary Building Blocks for Novel Solid Dispersion Matrix: Industrial and Ecological Paradigm to Enhance Dissolution Profile of Dapagliflozin. [PDF]

Pharmaceutics
Sherif AY, Altamimi MA, Elzayat EM.
europepmc   +1 more source

Cardiovascular Diseases and Cancer: Convergent Proteostasis Networks at the Crossroads of Mechanisms and Therapeutic Opportunities

MedComm, Volume 7, Issue 8, August 2026.
The disruption of proteostasis, encompassing the ubiquitin–proteasome system, autophagy, UPR/ER stress, and chaperone function, represents a fundamental mechanism shared by both cancer and cardiovascular diseases. While these pathways frequently facilitate tumor progression, they are crucial for maintaining proteostasis in cardiac tissue. Consequently,
Jacob Eli García Torres, Norbert Frey, Ashraf Yusuf Rangrez   +2 more
wiley   +1 more source

Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants. [PDF]

Nat Med
Marston NA, Kany S, Melloni GEM, Jurgens SJ, Kamanu FK, Lai YP, Rämö JT, Raz I, Wiviott SD, Ellinor PT, Sabatine MS, Ruff CT.   +11 more
europepmc   +1 more source

Type 2 Diabetes Mellitus: Molecular Pathogenesis and Therapeutic Interventions

MedComm, Volume 7, Issue 8, August 2026.
This graphical summary illustrates the multiorgan therapeutic landscape for Type 2 diabetes mellitus (T2D), integrating molecular pathogenesis with modern treatment strategies. It depicts how current interventions, including SGLT2 inhibitors, GLP‐1 receptor agonists, and insulin secretagogues, target key organs—kidney, pancreas, gastrointestinal tract,
Shinuan Fei, Xiyue Xiong, Lu Zhang, Jian Zhang, Lawrence W. C. Chan, Hong Jiang, Qingqing Xiong, Changtao Hu, Jie Chen, Sijun Yang   +9 more
wiley   +1 more source

Direct dapagliflozin exposure enhances respiration and membrane hyperpolarization in isolated cardiac mitochondria. [PDF]

Front Physiol
de Souza IIA, da Rosa CFM, Marinho LE, Coutinho MB, Moraes CDS, de Carvalho ACC, Nascimento JHM, Pinto LMO.   +7 more
europepmc   +1 more source

Active Safety Surveillance Using Real‐World Evidence (ASSURE) Implementation: Transparent and Reproducible Real‐World Evidence Standardized Framework to Support Safety Signal Evaluation

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 8, August 2026.
ABSTRACT Purpose To summarize experience with Johnson & Johnson's novel Active Safety Surveillance Using Real‐world Evidence (ASSURE) program for producing efficient, transparent, applicable, and impactful RWE to support routine pharmacovigilance processes.
Kevin Haynes, Jenna Reps, Jill Hardin, Eva‐Maria Didden, James Gilbert, Joel Swerdel, Justin Bohn, Mitchell M. Conover, Amir Sarayani, Anthony G. Sena, Emily Yost, Valerie van Baalen, Kourtney Davis, Patrick Ryan, Martijn Schuemie   +14 more
wiley   +1 more source

Real-World Experience With Dapagliflozin in Non-diabetic Chronic Kidney Disease: A Case Series From India. [PDF]

Cureus
Pal A, Sadhukhan S.
europepmc   +1 more source